Trial Outcomes & Findings for Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users (NCT NCT04881942)

NCT ID: NCT04881942

Last Updated: 2024-07-30

Results Overview

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

35 participants

Primary outcome timeframe

Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Results posted on

2024-07-30

Participant Flow

35 subjects (including alternates) used at least one test product during the Day -1 Trial. One subject discontinued from the study before randomization; 2 alternates were discontinued prior to randomization once the enrollment goal of 32 subjects was met. Therefore, a total of 32 subjects were randomized into the study. The 3 subjects who were discontinued prior to randomization constitute the "Day -1 Trial" group and are included in the Safety Population for AE reporting, and Baseline data.

Participant milestones

Participant milestones
Measure
ABDC
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4
BCAD
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4
CDBA
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4
DACB
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4
Day -1 Trial
Subjects who used at least one test product during the Visit 2, Day -1 product trial, but were not subsequently randomized.
Overall Study
STARTED
8
8
8
8
3
Overall Study
Completed Day 1 Product Use
8
8
8
8
0
Overall Study
Completed Day 2 Product Use
8
8
8
8
0
Overall Study
Completed Day 3 Product Use
8
8
8
8
0
Overall Study
Completed Day 4 Product Use
8
8
8
8
0
Overall Study
COMPLETED
8
8
8
8
0
Overall Study
NOT COMPLETED
0
0
0
0
3

Reasons for withdrawal

Reasons for withdrawal
Measure
ABDC
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4
BCAD
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4
CDBA
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4
DACB
Subjects administered 2 menthol and 2 non-menthol test e-vapor products: Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4
Day -1 Trial
Subjects who used at least one test product during the Visit 2, Day -1 product trial, but were not subsequently randomized.
Overall Study
Adverse Event
0
0
0
0
1
Overall Study
Alternates
0
0
0
0
2

Baseline Characteristics

Not all participants were asked to respond due to skip logics.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ABDC
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products: Product A (XL25F) on Day 1, Product B (XL40CB) on Day 2, Product D (XL40MB) on Day 3 and Product C (XL35WM) on Day 4
BCAD
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products: Product B (XL40CB) on Day 1, Product C (XL35WM) on Day 2, Product A (XL25F) on Day 3 and Product D (XL40MB) on Day 4
CDBA
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products: Product C (XL35WM) on Day 1 Product D (XL40MB) on Day 2, Product B (XL40CB) on Day 3 and Product A (XL25F) on Day 4
DACB
n=8 Participants
Subjects administered 2 menthol and and 2 non-menthol test e-vapor products: Product D (XL40MB) on Day 1, Product A (XL25F) on Day 2, Product C (XL35WM) on Day 3 and Product B (XL40CB) on Day 4
Day-1 Trial
n=3 Participants
Subjects who used at least one test product during the Visit 2, Day -1 product trial, but were not subsequently randomized
Total
n=35 Participants
Total of all reporting groups
Smoking Frequency in past 30 days
Missing Response / Skip Logics
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Age, Categorical
<=18 years
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
35 Participants
n=35 Participants
Age, Categorical
>=65 years
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Age, Continuous
35.3 Years
STANDARD_DEVIATION 12.02 • n=8 Participants
34.9 Years
STANDARD_DEVIATION 12.49 • n=8 Participants
41.1 Years
STANDARD_DEVIATION 15.95 • n=8 Participants
35.4 Years
STANDARD_DEVIATION 11.73 • n=8 Participants
37.7 Years
STANDARD_DEVIATION 14.22 • n=3 Participants
36.7 Years
STANDARD_DEVIATION 12.68 • n=35 Participants
Sex: Female, Male
Female
4 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
1 Participants
n=3 Participants
15 Participants
n=35 Participants
Sex: Female, Male
Male
4 Participants
n=8 Participants
4 Participants
n=8 Participants
5 Participants
n=8 Participants
5 Participants
n=8 Participants
2 Participants
n=3 Participants
20 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants
n=8 Participants
7 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
31 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Asian
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Black or African American
6 Participants
n=8 Participants
7 Participants
n=8 Participants
5 Participants
n=8 Participants
4 Participants
n=8 Participants
2 Participants
n=3 Participants
24 Participants
n=35 Participants
Race (NIH/OMB)
White
1 Participants
n=8 Participants
1 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
1 Participants
n=3 Participants
10 Participants
n=35 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Annual Household Income
<$20,000
4 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
7 Participants
n=8 Participants
1 Participants
n=3 Participants
18 Participants
n=35 Participants
Annual Household Income
$20,000-$29,999
0 Participants
n=8 Participants
4 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
8 Participants
n=35 Participants
Annual Household Income
$30,000-$39,999
1 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Annual Household Income
$40,000-$49,999
1 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Annual Household Income
$50,000-$59,999
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Annual Household Income
$75,000-$99,999
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Annual Household Income
No answer
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=3 Participants
2 Participants
n=35 Participants
Education
9-11 years
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
2 Participants
n=35 Participants
Education
12 years or GED
2 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
1 Participants
n=3 Participants
13 Participants
n=35 Participants
Education
Some college
3 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
1 Participants
n=3 Participants
14 Participants
n=35 Participants
Education
College graduate
1 Participants
n=8 Participants
1 Participants
n=8 Participants
2 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
4 Participants
n=35 Participants
Education
Other
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Education
No answer
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Height
168.6 cm
STANDARD_DEVIATION 8.16 • n=8 Participants
174.6 cm
STANDARD_DEVIATION 7.99 • n=8 Participants
170.7 cm
STANDARD_DEVIATION 10.28 • n=8 Participants
172.7 cm
STANDARD_DEVIATION 8.40 • n=8 Participants
177.7 cm
STANDARD_DEVIATION 22.64 • n=3 Participants
172.1 cm
STANDARD_DEVIATION 10.04 • n=35 Participants
Weight
80.4 kg
STANDARD_DEVIATION 17.90 • n=8 Participants
91.3 kg
STANDARD_DEVIATION 21.44 • n=8 Participants
82.8 kg
STANDARD_DEVIATION 11.91 • n=8 Participants
76.0 kg
STANDARD_DEVIATION 19.60 • n=8 Participants
77.1 kg
STANDARD_DEVIATION 11.46 • n=3 Participants
82.1 kg
STANDARD_DEVIATION 17.56 • n=35 Participants
Body Mass Index (BMI)
28.16 kg/m²
STANDARD_DEVIATION 5.535 • n=8 Participants
29.89 kg/m²
STANDARD_DEVIATION 6.014 • n=8 Participants
28.48 kg/m²
STANDARD_DEVIATION 3.699 • n=8 Participants
25.26 kg/m²
STANDARD_DEVIATION 5.177 • n=8 Participants
24.97 kg/m²
STANDARD_DEVIATION 6.035 • n=3 Participants
27.69 kg/m²
STANDARD_DEVIATION 5.254 • n=35 Participants
Employment Status
Wage Earner
2 Participants
n=8 Participants
6 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
2 Participants
n=3 Participants
16 Participants
n=35 Participants
Employment Status
Self-Employed
1 Participants
n=8 Participants
1 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
5 Participants
n=35 Participants
Employment Status
Unemployed > 1 year
1 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Employment Status
Unemployed < 1 year
2 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Employment Status
Homemaker
2 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Employment Status
Student
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
2 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Employment Status
Retired
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Employment Status
Unable to work
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
2 Participants
n=35 Participants
Military Experience
Active Duty
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Military Experience
Discharged More Than 1 Year Ago
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Military Experience
Never in military
6 Participants
n=8 Participants
7 Participants
n=8 Participants
8 Participants
n=8 Participants
7 Participants
n=8 Participants
3 Participants
n=3 Participants
31 Participants
n=35 Participants
Military Experience
No answer
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Marital Status
Single
5 Participants
n=8 Participants
4 Participants
n=8 Participants
6 Participants
n=8 Participants
6 Participants
n=8 Participants
2 Participants
n=3 Participants
23 Participants
n=35 Participants
Marital Status
Married/Partnered
1 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
5 Participants
n=35 Participants
Marital Status
Divorced/Separated/Widowed
0 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
4 Participants
n=35 Participants
Marital Status
No answer
2 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Sexual Identity
Heterosexual or Straight
7 Participants
n=8 Participants
7 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
33 Participants
n=35 Participants
Sexual Identity
No answer
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Previous Cigarette Usage
Yes
7 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
34 Participants
n=35 Participants
Previous Cigarette Usage
No
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
100 or more lifetime cigarettes
Yes
6 Participants
n=8 Participants
7 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
32 Participants
n=35 Participants
100 or more lifetime cigarettes
No
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
100 or more lifetime cigarettes
Missing Response / Skip Logics
2 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Smoke on a regular basis
Yes
7 Participants
n=8 Participants
7 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
33 Participants
n=35 Participants
Smoke on a regular basis
No
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Smoke on a regular basis
Missing Response / Skip Logics
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Length of Consistent Smoking
9.9 Years
STANDARD_DEVIATION 8.23 • n=7 Participants • Not all participants were asked to respond due to skip logics.
12.7 Years
STANDARD_DEVIATION 9.69 • n=7 Participants • Not all participants were asked to respond due to skip logics.
19.1 Years
STANDARD_DEVIATION 14.70 • n=8 Participants • Not all participants were asked to respond due to skip logics.
13.0 Years
STANDARD_DEVIATION 13.90 • n=8 Participants • Not all participants were asked to respond due to skip logics.
13.7 Years
STANDARD_DEVIATION 7.09 • n=3 Participants • Not all participants were asked to respond due to skip logics.
13.8 Years
STANDARD_DEVIATION 11.57 • n=33 Participants • Not all participants were asked to respond due to skip logics.
Smoking Frequency in past 30 days
Every Day
4 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
13 Participants
n=35 Participants
Smoking Frequency in past 30 days
Some Days
2 Participants
n=8 Participants
1 Participants
n=8 Participants
2 Participants
n=8 Participants
3 Participants
n=8 Participants
1 Participants
n=3 Participants
9 Participants
n=35 Participants
Smoking Frequency in past 30 days
Not at all
1 Participants
n=8 Participants
2 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
1 Participants
n=3 Participants
11 Participants
n=35 Participants
Daily Cigarette Use
9.7 number of cigarettes
STANDARD_DEVIATION 5.96 • n=6 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
9.0 number of cigarettes
STANDARD_DEVIATION 4.30 • n=5 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
9.6 number of cigarettes
STANDARD_DEVIATION 5.55 • n=5 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
2.8 number of cigarettes
STANDARD_DEVIATION 2.22 • n=4 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
14.0 number of cigarettes
STANDARD_DEVIATION 8.49 • n=2 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
8.6 number of cigarettes
STANDARD_DEVIATION 5.64 • n=22 Participants • Based on each subject's smoking history, not all subjects were required to answer this question.
Menthol Cigarettes Regularly
Yes
6 Participants
n=8 Participants
4 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=8 Participants
2 Participants
n=3 Participants
19 Participants
n=35 Participants
Menthol Cigarettes Regularly
No
0 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
3 Participants
n=35 Participants
Menthol Cigarettes Regularly
Missing Response / Skip Logics
2 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
1 Participants
n=3 Participants
13 Participants
n=35 Participants
Daily Smoking
Yes
4 Participants
n=8 Participants
4 Participants
n=8 Participants
5 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=3 Participants
16 Participants
n=35 Participants
Daily Smoking
No
2 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=3 Participants
6 Participants
n=35 Participants
Daily Smoking
Missing Response / Skip Logics
2 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
1 Participants
n=3 Participants
13 Participants
n=35 Participants
Previously Quit Smoking
Yes
2 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
7 Participants
n=35 Participants
Previously Quit Smoking
No
4 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=8 Participants
1 Participants
n=3 Participants
15 Participants
n=35 Participants
Previously Quit Smoking
Missing Response / Skip Logics
2 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
1 Participants
n=3 Participants
13 Participants
n=35 Participants
Quit Smoking Completely
Yes
1 Participants
n=8 Participants
2 Participants
n=8 Participants
3 Participants
n=8 Participants
4 Participants
n=8 Participants
0 Participants
n=3 Participants
10 Participants
n=35 Participants
Quit Smoking Completely
No
6 Participants
n=8 Participants
5 Participants
n=8 Participants
5 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=3 Participants
23 Participants
n=35 Participants
Quit Smoking Completely
Missing Response / Skip Logics
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Current Quit Smoking Duration
< 6 months
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Current Quit Smoking Duration
> 6 months
1 Participants
n=8 Participants
2 Participants
n=8 Participants
3 Participants
n=8 Participants
3 Participants
n=8 Participants
0 Participants
n=3 Participants
9 Participants
n=35 Participants
Current Quit Smoking Duration
Missing Response / Skip Logics
7 Participants
n=8 Participants
6 Participants
n=8 Participants
5 Participants
n=8 Participants
4 Participants
n=8 Participants
3 Participants
n=3 Participants
25 Participants
n=35 Participants
Previous E-Cigarette Usage
Yes
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
35 Participants
n=35 Participants
Previous E-Cigarette Usage
No
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 1
2 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
4 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 2
1 Participants
n=8 Participants
4 Participants
n=8 Participants
2 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=3 Participants
8 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 3
4 Participants
n=8 Participants
2 Participants
n=8 Participants
5 Participants
n=8 Participants
6 Participants
n=8 Participants
0 Participants
n=3 Participants
17 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 1 + Type 2
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 1 + Type 3
1 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
2 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 2 + Type 3
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
1 Participants
n=3 Participants
2 Participants
n=35 Participants
Type of e-Cigarette and e-Vapor Product Use
Type 1 + Type 2 + Type 3
0 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Number of Days of e-cigarette Use in Past Week
6.0 days
STANDARD_DEVIATION 1.20 • n=8 Participants
6.6 days
STANDARD_DEVIATION 0.74 • n=8 Participants
6.6 days
STANDARD_DEVIATION 1.06 • n=8 Participants
6.8 days
STANDARD_DEVIATION 0.46 • n=8 Participants
7.0 days
STANDARD_DEVIATION 0.00 • n=3 Participants
6.5 days
STANDARD_DEVIATION 0.89 • n=35 Participants
30 Day Disposable E-Cigarette/Cartridge Count
0.6 E-Cigarettes/Cartridges
STANDARD_DEVIATION 0.74 • n=8 Participants
0.6 E-Cigarettes/Cartridges
STANDARD_DEVIATION 0.74 • n=8 Participants
0.3 E-Cigarettes/Cartridges
STANDARD_DEVIATION 0.46 • n=8 Participants
0.9 E-Cigarettes/Cartridges
STANDARD_DEVIATION 1.64 • n=8 Participants
3.7 E-Cigarettes/Cartridges
STANDARD_DEVIATION 5.51 • n=3 Participants
0.9 E-Cigarettes/Cartridges
STANDARD_DEVIATION 1.85 • n=35 Participants
Milliliters of E-Liquid/day in last 30 Days
3.6 ml/day
STANDARD_DEVIATION 6.72 • n=8 Participants
2.1 ml/day
STANDARD_DEVIATION 3.31 • n=8 Participants
4.6 ml/day
STANDARD_DEVIATION 6.70 • n=8 Participants
3.5 ml/day
STANDARD_DEVIATION 3.12 • n=8 Participants
2.0 ml/day
STANDARD_DEVIATION 3.46 • n=3 Participants
3.3 ml/day
STANDARD_DEVIATION 4.94 • n=35 Participants
e-Cigarette Length of Use
17.8 months
STANDARD_DEVIATION 10.98 • n=8 Participants
14.5 months
STANDARD_DEVIATION 6.02 • n=8 Participants
22.5 months
STANDARD_DEVIATION 15.96 • n=8 Participants
17.8 months
STANDARD_DEVIATION 8.70 • n=8 Participants
11.3 months
STANDARD_DEVIATION 11.02 • n=3 Participants
17.5 months
STANDARD_DEVIATION 10.90 • n=35 Participants
e-Cigarette Use Frequency in Past 30 Days
Every Day
4 Participants
n=8 Participants
8 Participants
n=8 Participants
6 Participants
n=8 Participants
7 Participants
n=8 Participants
3 Participants
n=3 Participants
28 Participants
n=35 Participants
e-Cigarette Use Frequency in Past 30 Days
Some Days
4 Participants
n=8 Participants
0 Participants
n=8 Participants
2 Participants
n=8 Participants
1 Participants
n=8 Participants
0 Participants
n=3 Participants
7 Participants
n=35 Participants
e-Cigarette Use Frequency in Past 30 Days
Not at all
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Quit E-Cigarettes in Last Year
Yes
1 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
1 Participants
n=35 Participants
Quit E-Cigarettes in Last Year
No
7 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
34 Participants
n=35 Participants
Plan to Quit Smoking
Yes
1 Participants
n=8 Participants
0 Participants
n=8 Participants
1 Participants
n=8 Participants
2 Participants
n=8 Participants
0 Participants
n=3 Participants
4 Participants
n=35 Participants
Plan to Quit Smoking
No
5 Participants
n=8 Participants
5 Participants
n=8 Participants
5 Participants
n=8 Participants
2 Participants
n=8 Participants
3 Participants
n=3 Participants
20 Participants
n=35 Participants
Plan to Quit Smoking
Missing Response / Skip Logics
2 Participants
n=8 Participants
3 Participants
n=8 Participants
2 Participants
n=8 Participants
4 Participants
n=8 Participants
0 Participants
n=3 Participants
11 Participants
n=35 Participants
Plan to Quit E-Cigarettes
Yes
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=8 Participants
0 Participants
n=3 Participants
0 Participants
n=35 Participants
Plan to Quit E-Cigarettes
No
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
8 Participants
n=8 Participants
3 Participants
n=3 Participants
35 Participants
n=35 Participants

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Nicotine Residue Summary Statistics by Test-Product Group
182.8 Micrograms
Standard Deviation 253.88
87.1 Micrograms
Standard Deviation 120.11
192.3 Micrograms
Standard Deviation 268.53
174.1 Micrograms
Standard Deviation 208.64

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Nicotine Residue Summary Statistics by Test-Product Group
0.9 Micrograms
Standard Deviation 0.69
0.9 Micrograms
Standard Deviation 0.66
0.9 Micrograms
Standard Deviation 0.66
0.9 Micrograms
Standard Deviation 0.70

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Nicotine Summary Statistics by Test Product Group
181.8 Micrograms
Standard Deviation 254.23
86.1 Micrograms
Standard Deviation 120.40
191.4 Micrograms
Standard Deviation 268.78
173.1 Micrograms
Standard Deviation 208.93

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Glycerin Residue Summary Statistics by Test-Product Group
5682.4 Micrograms
Standard Deviation 5156.04
5964.4 Micrograms
Standard Deviation 5029.33
5707.3 Micrograms
Standard Deviation 5015.41
6516.6 Micrograms
Standard Deviation 5387.80

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Glycerin Residue Summary Statistics by Test-Product Group
10.9 Micrograms
Standard Deviation 2.65
15.4 Micrograms
Standard Deviation 16.49
11.1 Micrograms
Standard Deviation 5.01
15.4 Micrograms
Standard Deviation 16.53

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Glycerin Summary Statistics by Test Product Group
5671.5 Micrograms
Standard Deviation 5155.84
5949.0 Micrograms
Standard Deviation 5033.63
5696.2 Micrograms
Standard Deviation 5015.99
6501.2 Micrograms
Standard Deviation 5385.54

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Menthol Residue Summary Statistics by Test-Product Group
31.3 Micrograms
Standard Deviation 15.12
0.4 Micrograms
Standard Deviation 0.13
0.4 Micrograms
Standard Deviation 0.08
22.1 Micrograms
Standard Deviation 9.99

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Menthol Residue Summary Statistics by Test-Product Group
0.4 Micrograms
Standard Deviation 0.08
0.5 Micrograms
Standard Deviation 0.42
0.4 Micrograms
Standard Deviation 0.08
0.4 Micrograms
Standard Deviation 0.08

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Menthol Summary Statistics by Test Product Group
30.9 Micrograms
Standard Deviation 15.12
-0.1 Micrograms
Standard Deviation 0.30
0.0 Micrograms
Standard Deviation 0.00
21.7 Micrograms
Standard Deviation 9.98

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Propylene Glycol Residue Summary Statistics by Test-Product Group
2675.8 Micrograms
Standard Deviation 3794.98
1697.6 Micrograms
Standard Deviation 2351.62
1047.7 Micrograms
Standard Deviation 1497.14
3343.4 Micrograms
Standard Deviation 4090.27

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Propylene Glycol Residue Summary Statistics by Test-Product Group
14.6 Micrograms
Standard Deviation 0.66
14.9 Micrograms
Standard Deviation 1.54
14.9 Micrograms
Standard Deviation 2.18
15.4 Micrograms
Standard Deviation 2.97

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Propylene Glycol Summary Statistics by Test Product Group
2661.2 Micrograms
Standard Deviation 3795.07
1682.7 Micrograms
Standard Deviation 2351.82
1032.8 Micrograms
Standard Deviation 1497.42
3328.0 Micrograms
Standard Deviation 4090.90

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Formaldehyde Residue Summary Statistics by Test-Product Group
1.2 Micrograms
Standard Deviation 0.85
1.0 Micrograms
Standard Deviation 0.74
1.1 Micrograms
Standard Deviation 0.95
1.3 Micrograms
Standard Deviation 0.92

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Formaldehyde Residue Summary Statistics by Test-Product Group
1.0 Micrograms
Standard Deviation 0.79
0.8 Micrograms
Standard Deviation 0.66
0.8 Micrograms
Standard Deviation 0.63
1.0 Micrograms
Standard Deviation 0.79

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Formaldehyde Summary Statistics by Test Product Group
0.27 Micrograms
Standard Deviation 0.329
0.19 Micrograms
Standard Deviation 0.241
0.33 Micrograms
Standard Deviation 0.650
0.35 Micrograms
Standard Deviation 0.326

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Acetaldehyde Residue Summary Statistics by Test-Product Group
0.50 Micrograms
Standard Deviation 0.000
0.50 Micrograms
Standard Deviation 0.000
0.50 Micrograms
Standard Deviation 0.000
0.50 Micrograms
Standard Deviation 0.000

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Acetaldehyde Residue Summary Statistics by Test-Product Group
0.50 Micrograms
Standard Deviation 0.000
0.50 Micrograms
Standard Deviation 0.000
0.50 Micrograms
Standard Deviation 0.000
0.50 Micrograms
Standard Deviation 0.000

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Acetaldehyde Summary Statistics by Test Product Group
0.0 Micrograms
Standard Deviation 0.00
0.0 Micrograms
Standard Deviation 0.00
0.0 Micrograms
Standard Deviation 0.00
0.0 Micrograms
Standard Deviation 0.00

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Acrolein Residue Summary Statistics by Test-Product Group
0.63 Micrograms
Standard Error 0.000
0.63 Micrograms
Standard Error 0.000
0.63 Micrograms
Standard Error 0.000
0.63 Micrograms
Standard Error 0.000

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table summarizes the amount of analyte present in exhaled breath after sham. The analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on the day the subject was assigned the indicated test product according to the randomization scheme. In the exhaled breath test product use session, one exhaled breath sample was collected using an empty cartridge and inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container (capturing the specific analyte). Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 sec) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Sham Acrolein Residue Summary Statistics by Test-Product Group
0.6 Micrograms
Standard Error 0.00
0.6 Micrograms
Standard Error 0.00
0.6 Micrograms
Standard Error 0.00
0.6 Micrograms
Standard Error 0.00

PRIMARY outcome

Timeframe: Data collected over an approximately 10-minute timeframe (2 consecutive exhaled breath samples of 5-minute durations each) on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Table presents difference in total analyte amount in exhaled breath samples between sham (inactive battery \& empty cartridge) and controlled test product use. Analyte was collected over an approximately 10-min collection period in the exhaled breath product use session on day the subject was assigned the indicated test product. In the exhaled breath test product use session, 1 exhaled breath sample was collected using an empty cartridge \& inactive battery \[sham condition\] followed by an exhaled breath sample using the test product. Each exhaled breath sample was collected separately into the same type of trapping container. Each sample consisted of all the exhaled breath occurring during 10 puffs, each with 5 second puff duration (+/- 1 sec), over \~5 min (one puff approximately every 30 secs) collected in the respective sample collection containers. Sham-corrected analyte amounts were computed by subtracting corresponding sham response values from test product response values.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Sham-Corrected Acrolein Summary Statistics by Test Product Group
0.0 Micrograms
Standard Error 0.00
0.0 Micrograms
Standard Error 0.00
0.0 Micrograms
Standard Error 0.00
0.0 Micrograms
Standard Error 0.00

SECONDARY outcome

Timeframe: Samples collected during the approximately 1 hour controlled exhaled breath product use session on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Difference in recorded weight of Sample 1, measured in grams, collected before and after product use in Exhaled Breath Sessions. Sample 1 was used to collect propylene glycol, glycerin, nicotine and menthol, and was collected approximately 1 hour before Sample 2.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Cartridge Weight (g) Change Summary Statistics for Sample 1 (Propylene Glycol, Glycerin, Nicotine, Menthol) by Test Product in the Exhaled-Breath Sessions
0.0367 Grams
Standard Deviation 0.012324
0.0352 Grams
Standard Deviation 0.008701
0.0337 Grams
Standard Deviation 0.011374
0.0402 Grams
Standard Deviation 0.012596

SECONDARY outcome

Timeframe: Samples collected during the approximately 1 hour controlled exhaled breath product use session on the day the subject was assigned to use the test product (Day 1 or Day 2 or Day 3 or Day 4 according to the randomization scheme)

Difference in recorded weight of Sample 2, measured in grams, collected before and after product use in Exhaled Breath Sessions, Sample 2 was used to collect formaldehyde, acetaldehyde and acrolein, and was collected approximately 1 hour after Sample 1.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Cartridge Weight (g) Change Summary Statistics for Sample 2 (Formaldehyde, Acetaldehyde, Acrolein) by Test Product in the Exhaled-Breath Sessions
0.0379 Grams
Standard Deviation 0.012395
0.0356 Grams
Standard Deviation 0.011530
0.0363 Grams
Standard Deviation 0.011936
0.0412 Grams
Standard Deviation 0.014581

SECONDARY outcome

Timeframe: Samples were collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Difference in recorded weight (measured in grams) by test product, per subject, collected before and after product use in ad libitum sessions

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Summary Statistics of Total Cartridge Weight Change by Test Product, Per Subject, During the Ad Libitum-Use Sessions
0.418 Grams
Standard Deviation 0.33120
0.534 Grams
Standard Deviation 0.43562
0.406 Grams
Standard Deviation 0.32699
0.469 Grams
Standard Deviation 0.36765

SECONDARY outcome

Timeframe: Samples were collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Change in cartridge weight (measured in grams) as measured before and after a 12-hour ad-libitum use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=35 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=42 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=39 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=39 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
0.369 Grams
Standard Deviation 0.23418
0.428 Grams
Standard Deviation 0.26613
0.310 Grams
Standard Deviation 0.22996
0.398 Grams
Standard Deviation 0.25131
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
0.383 Grams
Standard Deviation 0.21158
0.351 Grams
Standard Deviation 0.25264
0.381 Grams
Standard Deviation 0.24206
0.309 Grams
Standard Deviation 0.26700
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
0.293 Grams
Standard Deviation 0.06010
0.812 Grams
Standard Deviation 0
0.444 Grams
Standard Deviation 0
Total Weight Change by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
0.370 Grams
Standard Deviation 0.22882
0.407 Grams
Standard Deviation 0.25716
0.333 Grams
Standard Deviation 0.24023
0.385 Grams
Standard Deviation 0.24910

SECONDARY outcome

Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Number of puffs, by test product, per subject, taken during 12-hour ad libitum product use session

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=31 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Summary Statistics of Puff Count by Test Product During the Ad Libitum-Use Sessions
242.839 puffs
Standard Deviation 194.6732
292.375 puffs
Standard Deviation 204.2479
239.000 puffs
Standard Deviation 164.4613
246.375 puffs
Standard Deviation 170.3419

SECONDARY outcome

Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Seconds per puff taken, by test product, per subject, during 12-hour ad libitum product use session

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=30 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=31 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=30 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=31 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Average Puff Duration by Test Product During the Ad Libitum-Use Sessions
2.209 seconds per puff
Standard Deviation 0.75672
2.471 seconds per puff
Standard Deviation 1.01786
2.373 seconds per puff
Standard Deviation 1.10711
2.249 seconds per puff
Standard Deviation 0.89143

SECONDARY outcome

Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Total seconds puffing by test product, per subject, taken during 12-hour ad libitum product use session

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=30 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=31 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=30 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=31 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Puff Duration by Test Product During the Ad Libitum-Use Sessions
517.733 Seconds
Standard Deviation 386.5348
726.028 Seconds
Standard Deviation 551.0662
589.204 Seconds
Standard Deviation 435.7242
575.807 Seconds
Standard Deviation 442.4253

SECONDARY outcome

Timeframe: Data was collected over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Total cartridges used by test product, per subject, taken during 12-hour ad libitum product use session

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=31 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Cartridges Used by Test Product During the Ad Libitum-Use Sessions
1.129 Cartridges
Standard Deviation 0.34078
1.313 Cartridges
Standard Deviation 0.59229
1.219 Cartridges
Standard Deviation 0.49084
1.219 Cartridges
Standard Deviation 0.49084

SECONDARY outcome

Timeframe: Data was collected at the end of the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Visual Analog Scale (VAS) measuring self-reported response to "Use the product again" questionnaire was collected after each product use session. The questionnaire consists of a single question ("If given the opportunity, I would want to use this product again"). Participants indicated their willingness to use the product again by pointing to a line measuring 100mm, with scores measured from left to right and ranging between 0 to 100 mm. Scores closer to the right, and thus higher on the scale, indicated a greater willingness to utilize the product again. Raw scores were converted to a binary score as follows: VAS scores \< 50 mm ≈ unwillingness to use the product again, and VAS scores ≥ 50 mm ≈ willingness to use product again.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Summary of Binary VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Want to Use
28 Participants
29 Participants
29 Participants
27 Participants
Summary of Binary VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Do not Want to Use
4 Participants
3 Participants
3 Participants
5 Participants

SECONDARY outcome

Timeframe: Data was collected at the end of the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Visual Analog Scale (VAS) measuring self-reported response to willingness to use study product again. Questionnaire was collected after each product use session. Questionnaire consists of a single question ("If given the opportunity, I would want to use this product again") with VAS response range from "Definitely Would Not" to "Don't Care" to "Definitely Would". Participants indicated their willingness to use the product again by pointing to a line measuring 100mm, with scores measured from left to right and ranging between 0 to 100 mm. Scores closer to the right, and thus higher on the scale, indicated a greater willingness to utilize the product again. The raw scores were then converted to a binary, "unwilling" vs. "willing" to use response. Additionally, a 3-level ordinal response was computed using "unwilling" (VAS \< 50 mm), "don't care" (VAS = 50 mm), and "willing" (VAS \> 50 mm).

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=32 Participants
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=32 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 Participants
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Summary of Ordinal VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Want to Use
28 Participants
29 Participants
29 Participants
26 Participants
Summary of Ordinal VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Don't Care
0 Participants
0 Participants
0 Participants
1 Participants
Summary of Ordinal VAS-Derived Categorical "Use Product Again Questionnaire" Scores by Test Product
Do Not Want to Use
4 Participants
3 Participants
3 Participants
5 Participants

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Puff Count by Test Product (Pooled Over Cartridges) during 12-hour ad-libitum-use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=35 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=42 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=37 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=39 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
220.032 Puffs
Standard Deviation 141.3675
247.156 Puffs
Standard Deviation 146.7016
197.065 Puffs
Standard Deviation 147.5464
217.969 Puffs
Standard Deviation 143.7912
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
176.750 Puffs
Standard Deviation 193.3190
164.250 Puffs
Standard Deviation 121.5680
195.600 Puffs
Standard Deviation 98.79929
117.333 Puffs
Standard Deviation 130.9712
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
66.500 Puffs
Standard Deviation 27.57716
322.000 Puffs
Standard Deviation 0
205.000 Puffs
Standard Deviation 0
Puff Count by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
215.086 Puffs
Standard Deviation 145.3491
222.762 Puffs
Standard Deviation 145.3878
200.243 Puffs
Standard Deviation 140.1773
202.154 Puffs
Standard Deviation 143.0770

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Average puff duration (measured in seconds) by Test Product (Pooled Over Cartridges) during 12-hour ad-libitum-use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=34 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=41 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=36 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=37 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
2.194 Seconds
Standard Deviation 0.73162
2.487 Seconds
Standard Deviation 1.05031
2.369 Seconds
Standard Deviation 1.10274
2.275 Seconds
Standard Deviation 0.92685
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
2.685 Seconds
Standard Deviation 1.32845
2.674 Seconds
Standard Deviation 1.13172
3.111 Seconds
Standard Deviation 1.52758
3.004 Seconds
Standard Deviation 0.89069
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
4.761 Seconds
Standard Deviation 0.06038
3.598 Seconds
Standard Deviation 0
3.330 Seconds
Standard Deviation 0
Average Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
2.252 Seconds
Standard Deviation 0.81028
2.634 Seconds
Standard Deviation 1.13792
2.506 Seconds
Standard Deviation 1.17333
2.402 Seconds
Standard Deviation 0.94449

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Total Puff Duration (measured in seconds) by Test Product (pooled over cartridges) during 12-hour ad-libitum-use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=34 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=41 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=36 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=37 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 3
315.777 Seconds
Standard Deviation 127.2806
1158.612 Seconds
Standard Deviation 0
682.752 Seconds
Standard Deviation 0
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Overall
456.823 Seconds
Standard Deviation 278.4626
548.948 Seconds
Standard Deviation 352.5085
491.003 Seconds
Standard Deviation 309.3294
482.433 Seconds
Standard Deviation 288.8387
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 1
463.815 Seconds
Standard Deviation 273.8106
597.673 Seconds
Standard Deviation 366.5793
455.996 Seconds
Standard Deviation 299.0212
486.874 Seconds
Standard Deviation 274.7173
Total Puff Duration by Test Product and Individual Cartridge During the Ad-Libitum-Use Sessions
Cartridge 2
404.380 Seconds
Standard Deviation 352.2326
418.433 Seconds
Standard Deviation 293.8095
567.524 Seconds
Standard Deviation 247.0947
414.832 Seconds
Standard Deviation 411.0123

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Change in cartridge weight (measured in grams) as measured before and after a 12-hour ad-libitum use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=10 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=7 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Weight Change by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
0.656 Grams
Standard Deviation 0.15309
0.623 Grams
Standard Deviation 0.24705
0.315 Grams
Standard Deviation 0.18197
0.664 Grams
Standard Deviation 0.19375

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Average puff duration (measured in seconds) by Test Product, per completed cartridge, during a 12-hour ad-libitum use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=8 Participants
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=6 Participants
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Average Puff Duration by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
2.491 Seconds
Standard Deviation 0.60612
3.033 Seconds
Standard Deviation 1.30359
3.004 Seconds
Standard Deviation 1.27635
3.019 Seconds
Standard Deviation 0.93719

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Puff count by Test Product, per completed cartridge, during a 12-hour ad-libitum use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=10 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=7 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Puff Count by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
311.400 Puffs
Standard Deviation 171.0111
298.300 Puffs
Standard Deviation 155.1444
159.714 Puffs
Standard Deviation 108.9567
280.000 Puffs
Standard Deviation 137.6311

SECONDARY outcome

Timeframe: Over the 12-hour ad libitum product use session on the day the subject was assigned the test product (according to the randomization scheme)

Population: Cartridges of products utilized by participants during 12-hour ad-libitum-use session

Total Puff Duration (measured in seconds) by Test Product, per completed cartridge, during a 12-hour ad-libitum use session of the product.

Outcome measures

Outcome measures
Measure
e-Vapor Product D
n=5 Cartridges
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
e-Vapor Product A
n=10 Cartridges
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=7 Cartridges
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=7 Cartridges
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
Total Puff Duration by Test Product, Per Completed Cartridge, During the Ad-Libitum-Use Sessions
729.328 Seconds
Standard Deviation 317.4452
814.728 Seconds
Standard Deviation 350.9879
432.943 Seconds
Standard Deviation 240.6142
766.922 Seconds
Standard Deviation 307.3669

Adverse Events

e-Vapor Product A

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

e-Vapor Product B

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

e-Vapor Product C

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

e-Vapor Product D

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Day -1 Product Trial Non-randomized Subjects

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
e-Vapor Product A
n=32 participants at risk
Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product
e-Vapor Product B
n=32 participants at risk
Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product
e-Vapor Product C
n=32 participants at risk
Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\]) e-Vapor Product C: e-Vapor product
e-Vapor Product D
n=32 participants at risk
Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
Day -1 Product Trial Non-randomized Subjects
n=3 participants at risk
Subjects who were not randomized after participating in the Day -1 Product Trial using all study products including: Product XL25F = Test e-vapor product (EVP) (formerly marketed by Nu Mark LLC as MarkTen® XL Fusion \[2.5% nicotine by weight {NBW}\]) e-Vapor Product A: e-Vapor product Product XL40CB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Classic \[4.0% NBW\]) e-Vapor Product B: e-Vapor product Product XL35WM = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Winter Mint \[3.5% NBW\] e-Vapor Product C: e-Vapor product Product XL40MB = Test EVP (formerly marketed by Nu Mark LLC as MarkTen® XL Bold Menthol \[4.0% NBW\]) e-Vapor Product D: e-Vapor product
Gastrointestinal disorders
Constipation
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Skin and subcutaneous tissue disorders
Rash
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Nervous system disorders
Headache
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Nervous system disorders
Dizziness
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Gastrointestinal disorders
Oral Discomfort
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Gastrointestinal disorders
Vomiting
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Injury, poisoning and procedural complications
Skin abrasion
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Musculoskeletal and connective tissue disorders
Back pain
3.1%
1/32 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/3 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
0.00%
0/32 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.
33.3%
1/3 • Number of events 1 • Adverse Event (AE) data collected for entire study duration: approximately 34 days from Visit 1 (screening) through End of Study for each individual subject.
Review of adverse events conducted by study staff at each study visit and documented in both source documentation and electronic Case Report Form.

Additional Information

Jeffery Edmiston, Functional Director Clinical Research

Altria

Phone: 8043352366

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place